相关实验视频

Updated: Jun 18, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

自体主导多囊性病 (EMPA-PKD) 患者的empagliflozin:随机对照试验的研究协议

Elisabeth Bahlmann-Kroll¹, Sebastian Häckl², Stefanie Kramer¹

¹Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany.

|December 15, 2024

概括

这项研究调查了empagliflozin在自体主导多囊性病 (ADPKD) 患者的安全性. 它评估SGLT2抑制剂是否影响囊生长和功能,有或没有tolvaptan.

科学领域:

腎臟病學 (nephrology) 是一種醫學.
临床药理学临床药理学
医疗成像医学成像

背景情况:

自体主导多囊性脏病 (ADPKD) 是一种遗传性脏疾病,其特征是囊的形成和生长,导致腹膜细胞的破坏和潜在的末期脏病.
托尔瓦普坦是唯一批准用于减缓ADPKD进展的药物;然而,在ADPKD患者中,-葡萄糖载体2抑制剂 (SGLT2i) 的安全性和有效性仍未确立.
人们担心SGLT2i可能会加剧囊生长并加速ADPKD的功能下降,因为这些患者被排除在之前的SGLT2i试验之外.

研究的目的:

评估SGLT2抑制剂empagliflozin在患有快速进展的ADPKD的患者中的安全性.
评估empagliflozin对功能和囊生长的影响,无论是否同时接受托尔瓦普坦治疗.
研究SGLT2抑制剂对ADPKD进展的潜在不良影响.

主要方法:

一项由研究人员发起的,双盲,随机,安慰剂控制的临床试验,涉及44名患有快速进展的ADPKD的患者.
参与者将接受empagliflozin (10毫克/天) 或安慰剂18个月,分层使用tolvaptan.
主要终点:用MRI测量脏总体积的变化;次要终点:淋巴细胞过率 (GFR) 的变化. 额外的终点包括可佩,白蛋白尿和血压.

主要成果:

该部分尚未提供,因为试验正在进行中.
目前正在进行数据收集和分析,以确定主要和次要终点.
关于empagliflozin在ADPKD患者的安全性和疗效的临时或最终结果将在研究完成后发表.

结论:

该EMPA-PKD试验对于了解ADPKD中SGLT2抑制剂的安全性概况至关重要.
这些发现将为在ADPKD患者中使用empagliflozin的临床实践提供信息,并可能提供新的治疗途径.
该研究旨在提供证据,以解决目前关于ADPKD中SGLT2i影响的知识差距,指导未来的研究和治疗策略.

关键词:

成年人脏病学脑神经学 (NEPHROLOGY) 是一个学科.腎臟病學 (nephrology) 是一種醫學.

更多相关视频

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium

Published on: September 1, 2015

Direct Drug Delivery to Kidney via the Renal Artery

Direct Drug Delivery to Kidney via the Renal Artery

Published on: April 17, 2021

相关概念视频

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area. This equation is...

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...

Chronic Kidney Disease III: Interprofessional Care

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...

Diabetic Nephropathy

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...